Beneficial Renal Effects of CS-905, a Novel Dihydropyridine Calcium Blocker, in SHR

• Published in: Japanese journal of pharmacology Vol. 51; no. 4; pp. 501 - 508
• Main Authors: OIZUMI, Kiyoshi, NISHINO, Hiroshi, MIYAMOTO, Masaaki, FUKUSHIGE, Junichiro, FUKAMI, Masaharu, KOIKE, Hiroyuki
• Format: Journal Article
• Language: English
• Published: The Japanese Pharmacological Society 1989
• ISSN: 0021-5198; 1347-3506
• DOI: 10.1254/jjp.51.501

CS-905 is a potent dihydropyridine calcium blocker that has a gradual and long-lasting antihypertensive action with little tachycardia in SHR. In this study, we investigated chronic and acute effects of CS-905 on renal functions in SHR. To examine the chronic effects, 23 week-old male SHR were treated with CS-905 (1 or 3 mg/kg/day, p.o.) or 0.3% CMC (carboxymethylcellulose). After the 15 weektreatment, the agent dose-relatedly lowered systolic blood pressure measured 24 hr after the final administration (184±2 and 173±3 mmHg at 1 and 3 mg/kg/day vs. 218±4 mmHg for the control group). Natriuresis and the reduction of urinary protein excretion were also observed in the CS-905 treated groups. Urinary NAG (N-acetyl-β-D-glucosaminidase) activity tended to decrease, but not significantly. Histopathological changes observed in the SHR kidney were reduced by chronic treatment with CS-905. On a single oral administration in 38 week-old SHR, CS-905 caused natriuresis at a dose of 3 mg/kg, but did not affect urinary protein excretion and urinary NAG activity. These effects of CS-905 on renal functions may be beneficial in the treatment of hypertension.